Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 5/20 | 0.52 |
| ▸ | ICAM1 | P05362 | 5/20 | 0.52 |
| ▸ | ITGAL | P20701 | 5/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21434143 | 0.88 | FAAH (0.42) | ITGB2ICAM1ITGALKMOFAAH | |
| SCHEMBL21433914 | 0.87 | ITGB2 (0.47) | ITGB2ICAM1ITGALLRRK2KMO | |
| SCHEMBL21434000 | 0.84 | ITGB2 (0.51) | ITGB2ICAM1ITGALKMOFAAH | |
| SCHEMBL21434085 | 0.84 | EPHX2 (0.44) | ITGB2ICAM1ITGALKMOFAAH | |
| SCHEMBL21434147 | 0.84 | NPC1 (0.53) | ITGB2ICAM1ITGALKMOFAAH | |
| SCHEMBL21433974 | 0.84 | ITGB2 (0.54) | ITGB2ICAM1ITGALKMOFAAH | |
| SCHEMBL21452690 | 0.84 | CHEK1 (0.44) | ITGB2ICAM1ITGALKMO | |
| SCHEMBL21434171 | 0.81 | EPHX2 (0.47) | ITGB2ICAM1ITGALKMOFAAH | |
| SCHEMBL21434051 | 0.81 | ITGB2 (0.49) | ITGB2ICAM1ITGALKMOFAAH | |
| SCHEMBL21434102 | 0.81 | DPP4 (0.48) | ITGB2ICAM1ITGALLRRK2KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| WO-2019193516-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | ITGB2 1763/4885ICAM1 4616/4885ITGAL 1975/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | ITGB2 1763/4885ICAM1 4616/4885ITGAL 1975/4885 |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3B | ITGB2 1693/4885ICAM1 4534/4885ITGAL 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.